Clinical Scorecard: Systemic Complement Activation Linked to Progression of Intermediate AMD
At a Glance
| Category | Detail |
|---|---|
| Condition | Intermediate Age-Related Macular Degeneration (iAMD) |
| Key Mechanisms | Systemic complement factors associated with progression to advanced AMD stages. |
| Target Population | Patients diagnosed with iAMD, average age 76, predominantly female (65%). |
| Care Setting | Longitudinal cohort study at University of Colorado School of Medicine. |
Key Highlights
- 34% of patients progressed to advanced AMD over a mean follow-up of 3.9 years.
- Lower systemic levels of C3 and C5 linked to disease progression.
- C3a/C3 and C5a/C5 ratios significantly associated with progression to geographic atrophy (GA).
- Moderate to good discrimination between progressors and nonprogressors using biomarker data.
- Classical complement pathway may be an important driver of iAMD progression.
Guideline-Based Recommendations
Diagnosis
- Utilize systemic complement biomarkers for risk stratification in iAMD.
Management
- Consider intravitreal complement inhibitors (e.g., pegcetacoplan, avacincaptad pegol) for patients with GA.
Monitoring & Follow-up
- Annual multimodal imaging and plasma sampling for patients with iAMD.
Risks
- Sample attrition and limited statistical power for distinguishing between GA and nAMD outcomes.
Patient & Prescribing Data
Patients with intermediate age-related macular degeneration (iAMD).
Potential for new bioassays to identify patients who may benefit from specific therapeutics.
Clinical Best Practices
- Focus on classical complement pathway in AMD research.
- Monitor systemic complement levels as potential biomarkers for progression.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
